Related Experiment Video
Updated: Jul 7, 2026
09:33
Preparation Of Neovascular Tissues from Human Glioma Tissues for Quantitative Proteomics Analysis of Tumor Angiogenesis
Published on: March 20, 2026
Antiangiogenic therapy and surgical practice.
A R John1, S R Bramhall, M C Eggo
1Queen Elizabeth Hospital, University Hospital Birmingham NHS Foundation Trust, Birmingham, UK. arj483@bham.ac.uk
The British Journal of Surgery
|February 19, 2008
Summary
Antiangiogenic therapy, including bevacizumab, offers a new treatment option. Despite initial challenges, ongoing research suggests a promising future for antiangiogenic drugs in clinical settings.
Area of Science:
- Oncology
- Pharmacology
- Biotechnology
Background:
- Antiangiogenic therapy represents a significant advancement in cancer treatment.
- Bevacizumab, a monoclonal antibody targeting vascular endothelial growth factor (VEGF), exemplifies this new therapeutic approach.
Purpose of the Study:
- To review the current status and future potential of antiangiogenic therapy.
- To assess the clinical impact and expectations of antiangiogenic drugs.
Main Methods:
- A comprehensive literature search was conducted.
- Databases searched included PubMed, National Institute for Health and Clinical Excellence, and National Institutes of Health websites up to August 2007.
Main Results:
- Many antiangiogenic drugs have not met initial expectations.
- Bevacizumab has been introduced as a novel antiangiogenic agent.
Conclusions:
- Antiangiogenic therapy is recognized as a potential fourth treatment modality.
- Despite setbacks, continued research supports a future role for antiangiogenic therapy in clinical practice.
More Related Videos
Related Concept Videos
01:10Mechanism of Angiogenesis
Blood vessel formation starts early during embryonic development, around day 7. In the extraembryonic yolk sac, mesodermal precursor cells called hemangioblast proliferate and differentiate into angioblast. Angioblasts express vascular endothelial growth factor receptor 2 or VEGFR2, which binds VEGF-A, a proangiogenic factor, guiding blood vessel formation. VEGF signaling promotes angioblasts to form a blood island in the developing embryo. Angioblasts further differentiate, giving rise to...
01:24Regulation of Angiogenesis and Blood Supply
Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits. Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl hydroxylase and factor...
01:26Aneurysm III: Interprofessional Care
Aneurysm management involves either conservative medical therapy or surgical intervention, depending on the size and symptoms of the aneurysm. Conservative management is generally reserved for smaller, asymptomatic aneurysms, while larger or symptomatic aneurysms often necessitate surgical repair.Conservative Medical TherapyFor small, asymptomatic aneurysms, particularly abdominal aortic aneurysms (AAA) less than 5.5 centimeters in diameter, conservative medical therapy is recommended. This...
01:22Aneurysm IV: Nursing Management
Vigilant monitoring for aneurysm rupture is essential for patients undergoing aortic surgery.Preoperative Nursing ManagementContinuously monitor the patient for manifestations of aneurysm rupture, such as pallor, weakness, tachycardia, hypotension, abdominal, back, groin, or periumbilical pain, changes in consciousness, and a pulsating abdominal mass. Regularly assess the patient's peripheral pulses.Instruct the patient to consume a clear liquid diet the day before surgery and administer...
01:29Venous Thrombosis III: Interprofessional Care
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...